Skip to main content
. 2017 Jul 8;8(49):84659–84670. doi: 10.18632/oncotarget.19109

Figure 3. Combined dacomitinib and PI3K-mTOR inhibitor in PTEN-deficient PDX.

Figure 3

Tumor growth of A. triple-negative breast cancer PDX (TNBC), KRAS mutant (G12R) low-grade ovarian cancer (LGSOC) and TP53 (R181P) and KRAS (G12C) mutant lung adenocarcinoma (LADC). The TNBC and LGSOC models were treated with vehicle, PF-05212384 (10 mg/kg, twice weekly, intravenously, dacomitinib (3 mg/kg daily, oral gavage) or the combination of both agents. The LADC was treated with vehicle, PF-04691502 (5 mg/kg, daily, oral gavage), dacomitinib (3 mg/kg daily, oral gavage) or the combination of both agents. Relative tumor volumes are displayed as mean +/- SE. p: p value for daily tumor volume change for each arm in comparison to vehicle arm. TGI%: percentages of tumor growth inhibition in comparison to vehicle arm.